RESUMEN
Bronchiolitis is one of the main reasons for hospitalization, or outpatient visits, in the paediatric population, especially among infants in the winter season. Despite the high incidence of the disease, ideal medical work up and treatment are still a matter of debate in the literature and among physicians. However, the most recent guidelines and review of literature do agree on some points. These agreements can be retained and used to improve the treatment of bronchiolitis in our setting.
La bronchiolite est une des causes principales d'hospitalisation ou de consultation en pédiatrie, particulièrement chez les nourrissons pendant la saison hivernale. Malgré l'incidence importante de cette maladie, la prise en charge médicale «idéale¼ et son traitement restent controversés. Les recommandations récentes et les revues de la littérature s'accordent, tout de même, sur certains points qui peuvent être utilisés pour améliorer notre prise en charge de la bronchiolite.
Asunto(s)
Bronquiolitis , Bronquiolitis/terapia , Niño , Hospitalización , Humanos , Incidencia , Lactante , Estaciones del AñoRESUMEN
Introduction: Publication rates vary significantly among different scientific meetings, with many abstracts never being published as peer-reviewed articles. This issue has never been investigated in the Hypertension field in Argentina. Our purpose was to determine the proportion of abstracts presented at the Argentinian Congress of Hypertension meetings that were published as full articles in peer-reviewed indexed journals, the time lag to publication and the factors associated with successful publication. Methods: we conducted a PubMed search to identify peer-reviewed publications of abstracts presented at the Argentinian Congress of Hypertension meetings between 2006 and 2015, assessing publication rate along with the time lag to publication. We also extracted information about several abstract characteristics and, for those that got published, we recorded the date of publication and journal name with its impact factor and H index. Predictors of publication were analyzed using a multivariable model. Results: a total of 619 abstracts were presented between 2006 and 2015. The rate of conversion to full-text peer-reviewed articles by June 2017 was 28.1% (95%CI 24.7-31.8%), with a median time to publication of 15.7 months (IQR 8-30.9). On multivariable analysis, the independent predictors of publication were basic science category (OR 5 [95%CI 2.3-10.8], p<0.001), oral presentation (OR 2.8 [95%CI 1.6-4.9], p<0.001) and being an award winner for the presentation (OR 3 [95%CI 1.3-6.8], p=0.01). Conclusion: conversion rate to full peer-reviewed articles of abstracts presented at the Argentinian Congress of Hypertension meetings is far from ideal, with potential areas where efforts should be concentrated to improve dissemination of knowledge
Introducción: El porcentaje de resúmenes que se presentan en reuniones científicas y llegan a publicarse como manuscritos completos en revistas indexadas revisadas por pares es bajo. Este problema no ha sido investigado en el área de la hipertensión en Argentina. Nos propusimos determinar la proporción de resúmenes presentados en los congresos argentinos de hipertensión que llegan a publicarse en revistas indexadas, como artículos completos revisados por pares, el tiempo transcurrido hasta la publicación y los factores asociados a la misma. Métodos: Realizamos una búsqueda en PubMed para identificar las publicaciones en revistas con revisión por pares de los resúmenes presentados en los congresos argentinos de hipertensión entre los años 2006 y 2015, determinando el porcentaje de resúmenes que llegaron a publicarse y el tiempo transcurrido hasta la publicación. Registramos fecha de publicación y revista, con su factor de impacto e índice H. Construimos un modelo multivariable de regresión logística para determinar los factores independientemente asociados a la publicación. Resultados: Entre 2006 y 2015 se presentaron 619 resúmenes. La tasa de conversión de resúmenes en artículos revisados por pares a junio de 2017, fue del 28,1% (IC 95%: 24,7-31,8%) con una mediana de tiempo hasta la publicación de 15,7 meses (RIC: 8-30,9). Los factores predictivos independientes de la publicación fueron: categoría ciencia básica (OR: 5 [IC 95%: 2,3-10,8]; p<0,001), presentación oral (OR: 2,8 [IC 95%: 1,6-4,9]; p<0,001), y haber obtenido un premio al mejor trabajo (OR: 3 [IC 95%: 1,3-6,8]; p=0,01). Conclusión: La tasa de conversión de resúmenes en artículos revisados por pares presentados en los congresos argentinos de hipertensión a publicaciones en revistas indexadas dista de ser ideal, habiéndose identificado áreas donde la concentración de esfuerzos podría mejorar la difusión del conocimiento
Asunto(s)
Congresos como Asunto/estadística & datos numéricos , Hipertensión/epidemiología , Indización y Redacción de Resúmenes/normas , Revisión por Pares , Argentina/epidemiología , Indización y Redacción de Resúmenes/estadística & datos numéricos , Bibliometría , Factor de Impacto , Modelos LogísticosRESUMEN
INTRODUCTION: Publication rates vary significantly among different scientific meetings, with many abstracts never being published as peer-reviewed articles. This issue has never been investigated in the Hypertension field in Argentina. Our purpose was to determine the proportion of abstracts presented at the Argentinian Congress of Hypertension meetings that were published as full articles in peer-reviewed indexed journals, the time lag to publication and the factors associated with successful publication. METHODS: we conducted a PubMed search to identify peer-reviewed publications of abstracts presented at the Argentinian Congress of Hypertension meetings between 2006 and 2015, assessing publication rate along with the time lag to publication. We also extracted information about several abstract characteristics and, for those that got published, we recorded the date of publication and journal name with its impact factor and H index. Predictors of publication were analyzed using a multivariable model. RESULTS: a total of 619 abstracts were presented between 2006 and 2015. The rate of conversion to full-text peer-reviewed articles by June 2017 was 28.1% (95%CI 24.7-31.8%), with a median time to publication of 15.7 months (IQR 8-30.9). On multivariable analysis, the independent predictors of publication were basic science category (OR 5 [95%CI 2.3-10.8], p<0.001), oral presentation (OR 2.8 [95%CI 1.6-4.9], p<0.001) and being an award winner for the presentation (OR 3 [95%CI 1.3-6.8], p=0.01). CONCLUSION: conversion rate to full peer-reviewed articles of abstracts presented at the Argentinian Congress of Hypertension meetings is far from ideal, with potential areas where efforts should be concentrated to improve dissemination of knowledge.
RESUMEN
Febrile Seizures (FS), despite their usual benign clinical course, are still subject of controversies regarding the need for further investigation and treatment with anti-epileptic drugs (AEDs). Our study aimed to inventory the clinical findings, laboratory and imaging data associated with FS and eventually influencing their management. 275 episodes admitted with FS at the emergency ward of the Liege CHR over a 5 year period were retrospectively analyzed regarding precipitating factors; clinical features; laboratory, electroencephalographic, and imaging studies; as well as treatment response. FS represented 1.4% of admissions to the pediatric service. 31.3% of patients had a family history of seizure disorder. 9% percent of seizures were focal, 11.7% recurrent, and 12.3% prolonged (greater than 10 minutes). Upper respiratory tract and otorhinolaryngologic viral infections were the most often implicated provoking factors, occurring in 69.5% of patients. Laboratory, electroencephalographic and radiographic studies were normal in more than 90% of cases. 73.8% of seizures resolved without intervention. An AED was required to manage the remaining 26.2%. This study confirms the favorable outcomes of FS as demonstrated in previous studies. This happens without requiring AEDs for resolution, and without recurrence. Laboratory, electroencephalographic and imaging studies, as well as initiation of AEDs should be based primarily on clinical severity.
Asunto(s)
Convulsiones Febriles/epidemiología , Convulsiones Febriles/etiología , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Estudios Retrospectivos , Convulsiones Febriles/diagnósticoRESUMEN
Thirty male adult Wistar rats (300-/+10 g body weight) underwent either 5/6 nephrectomy (Nx, n=20) or sham operation (SHAM, n=10) to determine olpadronate effects in an experimental model of uremic bone disease. For a 38-day period, 10 rats received olpadronate (16microg/100g bw) once a week (Nx+OPD) and the other vehicle (Nx). SHAM received vehicle. At baseline, treatment onset (t=7 days) and end of study (t=45 days) calcium, phosphorus, creatinine, bone alkaline phosphatase (b-ALP) and deoxypyridinoline crosslinks (DPyr) were determined. At t=0 and t=45 bone mineral density (BMD) was measured by DXA. At t=45 the right tibia was removed for bone histology. There were no differences in serum calcium. Phosphorus increased in Nx and Nx+OPD compared to SHAM (pAsunto(s)
Enfermedades Óseas Metabólicas/tratamiento farmacológico
, Resorción Ósea/metabolismo
, Huesos/efectos de los fármacos
, Difosfonatos/uso terapéutico
, Uremia/complicaciones
, Fosfatasa Alcalina/sangre
, Fosfatasa Alcalina/efectos de los fármacos
, Aminoácidos
, Animales
, Densidad Ósea/efectos de los fármacos
, Enfermedades Óseas Metabólicas/etiología
, Calcio/sangre
, Calcio/orina
, Creatinina/sangre
, Creatinina/orina
, Modelos Animales de Enfermedad
, Riñón/cirugía
, Masculino
, Fósforo/sangre
, Ratas
RESUMEN
Acute nitric oxide synthase inhibition with N G-nitro-L-arginine methyl ester (L-NAME) on chronotropic and pressor responses was studied in anesthetized intact rats and rats submitted to partial and complete autonomic blockade. Blood pressure and heart rate were monitored intra-arterially. Intravenous L-NAME injection (7.5 mg/kg) elicited the same hypertensive response in intact rats and in rats with partial (ganglionic and parasympathetic blockade) and complete autonomic blockade (38 ± 3, 55 ± 6, 54 ± 5, 45 ± 5 mmHg, respectively; N = 9, P = NS). L-NAME-induced bradycardia at the time when blood pressure reached the peak plateau was similar in intact rats and in rats with partial autonomic blockade (43 ± 8, 38 ± 5, 46 ± 6 bpm, respectively; N = 9, P = NS). Rats with combined autonomic blockade showed a tachycardic response to L-NAME (10 ± 3 bpm, P<0.05 vs intact animals, N = 9). Increasing doses of L-NAME (5.0, 7.5 and 10 mg/kg, N = 9) caused a similar increase in blood pressure (45 ± 5, 38 ± 3, 44 ± 9 mmHg, respectively; P = NS) and heart rate (31 ± 4, 34 ± 3, 35 ± 4 bpm, respectively; P = NS). Addition of L-NAME (500 æM) to isolated atria from rats killed by cervical dislocation and rats previously subjected to complete autonomic blockade did not affect spontaneous beating or contractile strength (N = 9). In vivo results showed that L-NAME promoted a tachycardic response in rats with complete autonomic blockade, whereas the in vitro experiments showed no effect on intrinsic heart rate, suggesting that humoral mechanisms may be involved in the L-NAME-induced cardiac response
Asunto(s)
Animales , Masculino , Ratas , Sistema Nervioso Autónomo , Inhibidores Enzimáticos , Frecuencia Cardíaca , NG-Nitroarginina Metil Éster , Óxido Nítrico Sintasa , Análisis de Varianza , Bloqueo Nervioso Autónomo , Presión Sanguínea , Atrios Cardíacos , Ratas Sprague-DawleyRESUMEN
Acute nitric oxide synthase inhibition with N G-nitro-L-arginine methyl ester (L-NAME) on chronotropic and pressor responses was studied in anesthetized intact rats and rats submitted to partial and complete autonomic blockade. Blood pressure and heart rate were monitored intra-arterially. Intravenous L-NAME injection (7.5 mg/kg) elicited the same hypertensive response in intact rats and in rats with partial (ganglionic and parasympathetic blockade) and complete autonomic blockade (38 +/- 3, 55 +/- 6, 54 +/- 5, 45 +/- 5 mmHg, respectively; N = 9, P = NS). L-NAME-induced bradycardia at the time when blood pressure reached the peak plateau was similar in intact rats and in rats with partial autonomic blockade (43 +/- 8, 38 +/- 5, 46 +/- 6 bpm, respectively; N = 9, P = NS). Rats with combined autonomic blockade showed a tachycardic response to L-NAME (10 3 bpm, P<0.05 vs intact animals, N = 9). Increasing doses of L-NAME (5.0, 7.5 and 10 mg/kg, N = 9) caused a similar increase in blood pressure (45 +/- 5, 38 +/- 3, 44 +/- 9 mmHg, respectively; P = NS) and heart rate (31 +/- 4, 34 +/- 3, 35 +/- 4 bpm, respectively; P = NS). Addition of L-NAME (500 micro M) to isolated atria from rats killed by cervical dislocation and rats previously subjected to complete autonomic blockade did not affect spontaneous beating or contractile strength (N = 9). In vivo results showed that L-NAME promoted a tachycardic response in rats with complete autonomic blockade, whereas the in vitro experiments showed no effect on intrinsic heart rate, suggesting that humoral mechanisms may be involved in the L-NAME-induced cardiac response.
Asunto(s)
Sistema Nervioso Autónomo/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Frecuencia Cardíaca/efectos de los fármacos , NG-Nitroarginina Metil Éster/farmacología , Óxido Nítrico Sintasa/antagonistas & inhibidores , Análisis de Varianza , Animales , Bloqueo Nervioso Autónomo , Presión Sanguínea/efectos de los fármacos , Atrios Cardíacos , Masculino , Ratas , Ratas Sprague-DawleyRESUMEN
The influence of chronic nitric oxide synthase inhibition with N G-nitro-L-arginine methyl ester (L-NAME) on body fluid distribution was studied in male Wistar rats weighing 260-340 g. Extracellular, interstitial and intracellular spaces, as well as plasma volume were measured after a three-week treatment with L-NAME (70 mg/kg per 24 h in drinking water). An increase in extracellular space (16.1 ± 1.1 vs 13.7 ± 0.6 ml/100 g in control group, N = 12, P<0.01), interstitial space (14.0 ± 0.9 vs 9.7 ± 0.6 ml/100 g in control group, P<0.001) and total water (68.7 ± 3.9 vs 59.0 ± 2.9 ml/100 g, P<0.001) was observed in the L-NAME group (N = 8). Plasma volume was lower in L-NAME-treated rats (2.8 ± 0.2 ml/100 g) than in the control group (3.6 ± 0.1 ml/100 g, P<0.001). Blood volume was also lower in L-NAME-treated rats (5.2 ± 0.3 ml/100 g) than in the control group (7.2 ± 0.3 ml/100 g, P<0.001). The increase in total ratio of kidney wet weight to body weight in the L-NAME group (903 ± 31 vs 773 ± 45 mg/100 g in control group, P<0.01) but not in total kidney water suggests that this experimental hypertension occurs with an increase in renal mass. The fact that the heart weight to body weight ratio and the total heart water remained constant indicates that, despite the presence of high blood pressure, no modification in cardiac mass occurred. These data show that L-NAME-induced hypertension causes alterations in body fluid distribution and in renal mass
Asunto(s)
Animales , Masculino , Ratas , Inhibidores Enzimáticos/farmacología , Líquidos Corporales , NG-Nitroarginina Metil Éster , Óxido Nítrico Sintasa , Espacio Extracelular , Hipertensión/inducido químicamente , Riñón , Tamaño de los Órganos , Ratas Wistar , Volumen PlasmáticoRESUMEN
The influence of chronic nitric oxide synthase inhibition with N G-nitro-L-arginine methyl ester (L-NAME) on body fluid distribution was studied in male Wistar rats weighing 260-340 g. Extracellular, interstitial and intracellular spaces, as well as plasma volume were measured after a three-week treatment with L-NAME (approximately 70 mg/kg per 24 h in drinking water). An increase in extracellular space (16.1 +/- 1.1 vs 13.7 +/- 0.6 ml/100 g in control group, N = 12, P<0.01), interstitial space (14.0 +/- 0.9 vs 9.7 +/- 0.6 ml/100 g in control group, P<0.001) and total water (68.7 +/- 3.9 vs 59.0 +/- 2.9 ml/100 g, P<0.001) was observed in the L-NAME group (N = 8). Plasma volume was lower in L-NAME-treated rats (2.8 +/- 0.2 ml/100 g) than in the control group (3.6 +/- 0.1 ml/100 g, P<0.001). Blood volume was also lower in L-NAME-treated rats (5.2 +/- 0.3 ml/100 g) than in the control group (7.2 +/- 0.3 ml/100 g, P<0.001). The increase in total ratio of kidney wet weight to body weight in the L-NAME group (903 +/- 31 vs 773 +/- 45 mg/100 g in control group, P<0.01) but not in total kidney water suggests that this experimental hypertension occurs with an increase in renal mass. The fact that the heart weight to body weight ratio and the total heart water remained constant indicates that, despite the presence of high blood pressure, no modification in cardiac mass occurred. These data show that L-NAME-induced hypertension causes alterations in body fluid distribution and in renal mass.
Asunto(s)
Líquidos Corporales/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , NG-Nitroarginina Metil Éster/farmacología , Óxido Nítrico Sintasa/antagonistas & inhibidores , Animales , Espacio Extracelular/efectos de los fármacos , Hipertensión/inducido químicamente , Riñón/efectos de los fármacos , Masculino , Tamaño de los Órganos/efectos de los fármacos , Volumen Plasmático/efectos de los fármacos , Ratas , Ratas WistarRESUMEN
Meningococcemia is a severe Gram negative septicemia whose mortality may be as high as 30%. It occurs more frequently in children but the proportion of teenagers is increasing in Belgium. During the past decade, a slow but sustained rise in the incidence of this illness has been noted, with a predominance of the serogroup B. We describe the symptoms, which often are poor in the early stage, the different therapies, most of them being still under investigation, and the chemoprophylaxis. Without being alarmist, the diagnosis must be considered in any child with cutaneous rash, even atypical and tachycardia.